The field that spent thirty years being introduced with a smirk — cryonics adjacency, billionaire blood boys, immortality cranks — now publishes in the journals that once refused to review it. Aging biology has crossed the line from speculation to pipeline, and the pipeline has dates on it.
Three classes of intervention did the crossing. Senolytics, which clear the zombie cells that accumulate with age, are in phase-three trials for osteoarthritis and pulmonary fibrosis. Partial cellular reprogramming — briefly rewinding a cell’s epigenetic clock without erasing its identity — has restored vision in primates and attracted more capital than the rest of the field combined. And the unglamorous champion: the metabolic drugs everyone already knows, being re-trialed at scale for indications their inventors never imagined.
The biomarker breakthrough
None of this works as medicine without a way to measure aging faster than aging happens. That was the field’s quiet unlock: epigenetic clocks precise enough to detect a two-year change in biological age within a six-month trial. The FDA has not blessed aging as an indication — but it has accepted clock-based endpoints in two trial designs, which insiders describe as the whole ballgame arriving through a side door.
The first drug that slows aging won’t say so on the label. It will say osteoarthritis.
The distribution problem
Here is the fight the field can see coming and would rather not discuss. Every intervention in the pipeline will debut expensive, off-label, and cash-pay — available for years to precisely the demographic that already lives longest. A therapy that adds five healthy years, distributed by wealth, would widen the lifespan gap between rich and poor faster than any force in modern history.
The researchers know it. The regulators know it. The decade ahead will decide whether slowed aging becomes public health or private privilege — and that decision, unlike the biology, cannot be outsourced to a lab.
